PMID- 34821175
OWN - NLM
STAT- MEDLINE
DCOM- 20220210
LR  - 20220210
IS  - 1533-0338 (Electronic)
IS  - 1533-0346 (Print)
IS  - 1533-0338 (Linking)
VI  - 20
DP  - 2021 Jan-Dec
TI  - Pembrolizumab or Bevacizumab Plus Chemotherapy as First-Line Treatment of 
      Advanced Nonsquamous Nonsmall Cell Lung Cancer: A Retrospective Cohort Study.
PG  - 15330338211039676
LID - 10.1177/15330338211039676 [doi]
LID - 15330338211039676
AB  - Objective: Pembrolizumab and bevacizumab both have antitumor activity. According 
      to NCCN updated guideline the benefit of pembrolizumab or bevacizumab as a first 
      line in management of advanced nonsmall cell lung cancer (NSCLC) is documented in 
      randomized controlled studies. The study aimed to evaluate the response and 
      complications of patients with advanced NSCLC treated with pembrolizumab or 
      bevacizumab plus chemotherapy. Methods: This study was a retrospective cohort 
      study of patients with advanced nonsquamous NSCLC who received cisplatin with 
      pemetrexed combined with pembrolizumab (A group) or bevacizumab (B group) from 
      07/02/2018 to 07/03/2021 at Peking University Cancer Hospital. Progression-free 
      survival (PFS) was the primary outcome. The secondary outcomes included overall 
      survival (OS), objective response rate (ORR), disease control rate (DCR), 
      duration of response (DoR), and adverse events (AEs). Results: This study 
      included 66 patients, 34 in A group and 32 in B group. There were no differences 
      in median PFS (7.6 vs 9.9 months, P = .601). There were no differences in median 
      OS (23.1 vs 24.2 months, P = .782). There were no differences in ORR (57.6% vs 
      41.9%, P = .211) and DCR (93.9% vs 100.0%, P = .164) between 2 groups. The 
      occurrence of AEs was similar. No new safety signals were observed. Grade 3 to 4 
      treatment-related AEs occurred in 17 (50.0%) patients of A group and in 12 
      (37.5%) of B group (P > .05). Conclusion: The addition of pembrolizumab or 
      bevacizumab to pemetrexed plus cisplatin was well tolerated and resulted in a 
      clinically meaningful treatment benefit in advanced nonsquamous NSCLC. When 
      pembrolizumab is not suitable, bevacizumab plus chemotherapy may be an option.
FAU - Zhang, Jie
AU  - Zhang J
AD  - 12519Peking University Cancer Hospital & Institute, Beijing, China.
FAU - Wu, Di
AU  - Wu D
AD  - 12519Peking University Cancer Hospital & Institute, Beijing, China.
FAU - Zhang, Ziran
AU  - Zhang Z
AD  - 12519Peking University Cancer Hospital & Institute, Beijing, China.
FAU - Long, Jieran
AU  - Long J
AD  - 12519Peking University Cancer Hospital & Institute, Beijing, China.
FAU - Tian, Guangming
AU  - Tian G
AD  - 12519Peking University Cancer Hospital & Institute, Beijing, China.
FAU - Wang, Yang
AU  - Wang Y
AD  - 12519Peking University Cancer Hospital & Institute, Beijing, China.
FAU - Ma, Xiangjuan
AU  - Ma X
AD  - 12519Peking University Cancer Hospital & Institute, Beijing, China.
FAU - Chen, Xiaoling
AU  - Chen X
AD  - 12519Peking University Cancer Hospital & Institute, Beijing, China.
FAU - Han, Jindi
AU  - Han J
AD  - 12519Peking University Cancer Hospital & Institute, Beijing, China.
FAU - Hu, Weiheng
AU  - Hu W
AD  - 12519Peking University Cancer Hospital & Institute, Beijing, China.
FAU - Dai, Ling
AU  - Dai L
AD  - 12519Peking University Cancer Hospital & Institute, Beijing, China.
FAU - Nie, Jun
AU  - Nie J
AD  - 12519Peking University Cancer Hospital & Institute, Beijing, China.
FAU - Fang, Jian
AU  - Fang J
AUID- ORCID: 0000-0003-3697-4563
AD  - 12519Peking University Cancer Hospital & Institute, Beijing, China.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - Technol Cancer Res Treat
JT  - Technology in cancer research & treatment
JID - 101140941
RN  - 0 (Antibodies, Monoclonal, Humanized)
RN  - 04Q9AIZ7NO (Pemetrexed)
RN  - 2S9ZZM9Q9V (Bevacizumab)
RN  - DPT0O3T46P (pembrolizumab)
RN  - Q20Q21Q62J (Cisplatin)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Antibodies, Monoclonal, Humanized/administration & dosage
MH  - Antineoplastic Combined Chemotherapy Protocols/adverse effects/*therapeutic use
MH  - Bevacizumab/administration & dosage
MH  - Carcinoma, Non-Small-Cell Lung/*drug therapy
MH  - Cisplatin/administration & dosage
MH  - Female
MH  - Humans
MH  - Kaplan-Meier Estimate
MH  - Lung Neoplasms/*drug therapy
MH  - Male
MH  - Middle Aged
MH  - Pemetrexed/administration & dosage
MH  - Progression-Free Survival
MH  - Proportional Hazards Models
MH  - Response Evaluation Criteria in Solid Tumors
MH  - Retrospective Studies
MH  - Survival Rate
PMC - PMC8649085
OTO - NOTNLM
OT  - bevacizumab
OT  - chemotherapy
OT  - nonsquamous nonsmall cell lung cancer
OT  - pembrolizumab
OT  - response to treatment
COIS- Declaration of Conflicting Interests: The authors declared no potential conflicts 
      of interest with respect to the research, authorship, and/or publication of this 
      article.
EDAT- 2021/11/26 06:00
MHDA- 2022/02/11 06:00
PMCR- 2021/11/25
CRDT- 2021/11/25 08:42
PHST- 2021/11/25 08:42 [entrez]
PHST- 2021/11/26 06:00 [pubmed]
PHST- 2022/02/11 06:00 [medline]
PHST- 2021/11/25 00:00 [pmc-release]
AID - 10.1177_15330338211039676 [pii]
AID - 10.1177/15330338211039676 [doi]
PST - ppublish
SO  - Technol Cancer Res Treat. 2021 Jan-Dec;20:15330338211039676. doi: 
      10.1177/15330338211039676.